Solid papillary carcinoma with reverse polarity is a rare breast cancer of favorable prognosis that can be difficult to diagnose. We report here nine additional cases of this tumor, and we describe its morphologic, immunohistochemical and molecular profile in comparison to other types of papillary and micropapillary lesions of the breast that are intraductal papilloma with usual ductal hyperplasia, encapsulated papillary carcinoma, solid papillary carcinoma and invasive micropapillary carcinoma. We studied nine cases of this special papillary tumor and six of each other types mentioned above. We found that solid papillary carcinoma with reverse polarity harbor specific morphologic features as cuboid or tall cells with abundant eosinophilic cytoplasms located at the basal pole giving the impression of reverse nuclear polarity. Nuclei were sometimes grooved. Immunohistochemistry demonstrated the lack of myoepithelial cells, as in encapsulated papillary carcinoma and solid papillary carcinoma, questioning their invasive nature. Seven of nine solid papillary carcinoma with reverse polarity showed a low Ki67 proliferative index (Ki67 <5%). They showed expression of CK5/6 as in intraductal papilloma with usual ductal hyperplasia. They showed expression of calretinin and a low or lack of hormonal receptor (HR) expression that were not observed in other breast tumors studied. By whole-exome analysis, seven of nine solid papillary carcinomas with reverse polarity (78%) harbored a hotspot mutation in IDH2 (R172) that was totally absent in other groups. Six of nine tumors (67%) also harbored PRUNE2 mutation, including the two IDH2 wild-type cases. We also demonstrated for the first time in this breast tumor, immunostaining with a specific antibody IDH1/2 mutant R132/R172 (7/9) that can highlight IDH2 mutation. Moreover, transcriptomic analysis showed that proteoglycan pathway was significantly enriched. Our findings support the fact that solid papillary carcinoma with reverse polarity is a singular breast neoplasm that can be distinguished from other papillary breast tumors.
Introduction
Papillary lesions of the breast constitute a heterogeneous group of neoplasms including benign, atypical and malignant lesions (in situ or invasive). They represent about 5% of all breast lesions [1] . They are characterized by a specific architecture composed of papillae, centered by fibrovascular cores and lined by epithelial cells with or without underlying myoepithelial cells. Some of them are made of micropapillae that are devoid of fibrovascular cores [2] . These features are usually well recognized. Nevertheless, evaluation of papillary lesions remains problematic for most pathologists, because there are overlap features between these different lesions. Thereby, to separate these lesions with different prognoses, immunohistochemistry (IHC) is very useful or even essential. These tumors also display various genetic alterations, but they are till now not commonly used in the routine practice.
In 2003, Eusebi et al. [3] first reported five cases of a very rare breast papillary lesion, initially named breast tumor resembling the tall cell variant of papillary thyroid carcinoma because of its resemblance with papillary thyroid carcinoma. None of these five cases expressed thyroidspecific markers. Thanks to molecular studies that followed, it has been proven that these tumors were definitely not related to thyroid carcinoma, especially with lack of BRAF or RET alterations [4] . Since 2003, 37 additional cases of this rare breast tumor were reported [5] [6] [7] [8] [9] [10] [11] [12] . These tumors harbor specific histological and immunohistochemical features [2] and often consist of circumscribed solid nodules of epithelial cells arranged in nests or papillae. Epithelial cells are characterized by eosinophilic, cuboidal or tall cytoplasms, with altered nuclear polarity and nuclear grooves. The lack of myoepithelial cells between fibrovascular cores and epithelial cells is another distinctive feature. These tumors are considered as low-grade invasive carcinomas because lymph node invasion has been reported in only four cases [5, 6, 12] with one associated to bone metastasis [6] . Recently, Chiang et al. [10] analyzed a series of 13 of this exceptional papillary breast tumor at the molecular level and identified a somatic mutation of the IDH2 (isocitrate dehydrogenase 2) gene at R172 in 10 of them. They also described a concomitant mutation in the PIK3CA gene in eight of these ten tumors, and one TET2 gene mutation associated with a PIK3CA gene mutation in a wild-type IDH2 case. They proposed to name this entity solid papillary carcinoma with reverse polarity.
The purpose of the present study is to report nine additional cases of this tumor and to focus on their macroscopic, microscopic and immunophenotypic features in comparison with two types of frequent papillary lesions and one type of micropapillary lesion of the breast that are encountered in current practice. These differential diagnoses studied were intraductal papilloma with usual ductal hyperplasia, encapsulated papillary carcinoma, solid papillary carcinoma and invasive micropapillary carcinoma.
We also analyzed all these breast tumors in terms of genetic mutations and transcriptomic signatures by using next-generation sequencing to confirm the specific mutations previously described [9, 10] and to search for other specific genetic alterations.
Materials and methods

Cases
Nine tumors diagnosed as solid papillary carcinoma with reverse polarity were retrieved from the consultation cases files of three authors (LA, GM and ML-T). These cases (cases 1 to 9) came from different laboratories in France, between 2008 and 2017. Slides were reviewed, tumors were evaluated for their morphologic appearance and cases were included in the study.
To compare, six cases of invasive micropapillary carcinoma (10 to 15), of encapsulated papillary carcinoma (16 to 22) , of intraductal papilloma with usual ductal hyperplasia (22 to 27) and of solid papillary carcinoma (28 to 33) were randomly collected from databases of the Centre GeorgeFrancois Leclerc pathology departments and were included in the study.
Data on patient age at the time of diagnosis, breast side, gross inspection, tumor size, lymph node status, lymphovascular invasion, patients' management, recurrence and follow-up were collected for all these 33 breast lesions.
The samples from the tumor archives of each participating laboratory were centralized in the Centre GeorgesFrançois Leclerc for which the French authorities authorized for scientific research (AC-2014-2260). The study was approved by the ethical and scientific committee of the Centre Georges-François Leclerc.
Morphology and immunochemistry
Immunohistochemical analysis was performed using an automatic stainer (Ventana Benchmark XT system®, Roche™) with UltraView Universal DAB detection for each antibody. Antibodies used were: cytokeratin (CK) 5/6 and 7 (CK5/6, CK7), p63, calponin, estrogen receptor (ER), progesterone receptor (PR), HER2, androgen receptor (AR), gross cystic disease fluid protein-15 (GCDFP-15), TTF1, Calretinin, Ki67, chromogranin A and synaptophysin.
Due to the recent publication by Chiang et al. [10] , a complementary immunohistochemical test was performed in the present series, using IDH1/2 mutant (R132/R172) antibody (clone MsMAb-1, Merck Millipore) which is a specific antibody able to recognize the IDH2 mutant protein. Evaluation of immunolabeling was made for this last antibody by calculating a H-score (% of positive stained cells×intensity of the staining grade from 0 to 3, results of H-score must be ranged between 0 and 300).
All antibodies used and details regarding pretreatment, clones, dilutions, incubation times are summarized in Table 1 .
Molecular analysis
DNA and RNA extraction
Formalin-fixed paraffin-embedded tumors were analyzed by one pathologist to determine the tumor cell content. Samples were macrodissected to obtain a tumor cell content of 80% at least. DNA was extracted using the Maxwell-16 formalin-fixed paraffin-embedded Plus LEV DNA purification kit (Promega) according to the manufacturer's protocol. DNA quality was assessed by spectrophotometry with absorbance at 230, 260 and 280 nm. DNA was quantified using a fluorimetric assay with a Qubit device.
RNA was extracted using the Maxwell-16 LEV RNA formalin-fixed paraffin-embedded Purification kit (Promega) according to the manufacturer's protocol. RNA quality and quantity were assessed by spectrophotometry with absorbance at 230, 260 and 280 nm.
Exome analysis
A total of 200 ng of genomic DNA was fragmented with a Coveris device to obtain fragments around 300 bp. Then, libraries were constructed and captured by using SureSelect Human All Exon v6 kit (Agilent), following the manufacturer's protocol. Paired-end (2 × 151 bases) sequencing was performed on a NextSeq500 device (Illumina). Obtained sequences were aligned and annotated with the human Hg19 genome based on the SureSelect Human all Exon v6 manifest by using BWA and GATK algorithms. Only sequences with a read depth of 10×, a mutation allele frequency superior to 5% and a frequency in the general population inferior to 1% were conserved for the analysis.
RNA sequencing
RNA depleted of ribosomal RNA was used for the library preparation with a TruSeq RNA library Prep kit according to the manufacturer's instructions (Illumina). RNA sequencing was performed on a NextSeq500 device (Illumina). The libraries were sequenced with paired-end 76-base pair 'reads'. Analysis was performed with the splice junction mapper TopHat for Illumina on the human Hg19 genome. The files generated were processed with Cufflinks software to obtain annotated expressed genes in each studied subtype. 
Exome analysis
Gene mutations (whatever the nucleotide change) present in too many or too few patients were retrieved from the analysis (arbitrary thresholds were chosen). By this way, 1192 mutations were kept for further analysis. To select mutations specific to solid papillary carcinoma with reverse polarity and control samples, only mutations respectively (resp.) detected in more than 1/4 of the solid papillary carcinoma with reverse polarity samples (resp. 1/4 of the control samples) and less than 10% (resp. 1/4) in the other diagnostic group were kept.
RNA-sequencing
RNA-Seq data were aligned to the transcriptome and reference genome with TopHat 2.1.1. The reference genome was downloaded on the UCSC (University of California, Santa Cruz) Genome Browser (hg19). Fragments per kilobase of transcript per million (FPKM) were calculated using Cufflinks 2.2.1. Differential genes were selected using the Cuffdiff program from Cufflinks through the cummeRbund R package [13, 14] . Only genes specific to the solid papillary carcinoma with reverse polarity patients with the false discovery rate-adjusted p-value under 0.05 were kept; by this way, 76 genes were selected [15] . Intrinsic molecular subtype classification from RNA-sequencing results was based on the PAM50 gene set [16] . It was performed by nearest centroid method and Spearman's correlation on the log2 transform of the FPKM RNA-seq values using the Bioconductor package genefu [15] .
Results
Clinicopathologic features
A total of nine cases of solid papillary carcinoma with reverse polarity were retrieved. Six cases of each tumor controls were selected (six invasive micropapillary carcinoma, six encapsulated papillary carcinomas, six intraductal papillomas with usual hyperplasia and six solid papillary carcinomas).
The nine solid papillary carcinomas with reverse polarity occurred in women aged from 52 to 75 years (mean = 65.8 Table 2 Clinicopathologic features of solid papillary carcinoma with reverse polarity in the study years old). Three of them were discovered by mammography screening. For two patients, a single nodule was detected by palpation on physical examination. Information about the way of detection was not available for the other four patients. Five of them were localized in the left breast, four others in the right breast. Tumor size ranged from 9 to 40 mm (mean = 17 mm). Patient management always consisted in segmental resection, one patient had a sentinel lymph node procedure. For the three patients we had follow-up, there was no evidence of radiotherapy or chemotherapy. Clinicopathologic findings are listed in Table 2 .
On macroscopic inspection, all solid papillary carcinomas with reverse polarity always consisted of a relatively well-circumscribed single nodule. Only one was described as slightly irregular.
On microscopical examination, all the tumors showed a well-delimited lesion. A solid papillary architecture (7/9) and a cystic architecture (2/9) were observed ( Fig. 1a, b) . The solid papillary architecture consisted in nests closely packed or separated by a dense fibrous stroma (Fig. 2 ). Papillae were always observed, lined by neoplastic cells and centered by fibrovascular cores, sometimes containing foamy macrophages (3/9). In some areas of the tumor, a gyrate architecture was identified with concentric arrangement of the rows of epithelial cells.
In each tumor, neoplastic cells were columnar to cuboidal, and were positioned back to back. Cytoplasms were abundant, eosinophilic or clear. Mild nuclear atypia was observed. Nuclei were slightly increased in size, ovoid, sometimes grooved (Fig. 3) , with rare nuclear pseudoinclusions. One of the cases (case 9) showed small nucleoli. For all cases, chromatin was clear and no or rare mitotic figures or prominent nucleoli were observed. In each tumor, nuclei were localized at the apical side of the cytoplasm, far away from the basal layer, giving the impression of reverse polarity (Fig. 4a, b) . In all these cases myoepithelial cells surrounding the nodule or surrounding fibrovascular cores were always absent. Eosinophilic and dense secretions were noted in three of nine cases (Fig. 5) . No psammoma bodies or necrotic areas were observed.
For invasive micropapillary carcinoma, encapsulated papillary carcinoma, intraductal papilloma with usual ductal hyperplasia and solid papillary carcinoma, mean age for each tumor group was respectively 67.5, 69, 60 and 75.5 years.
The six cases of encapsulated papillary carcinoma and intraductal papilloma also consisted of a well-delimited intraductal or intracystic epithelial tumor, containing separated papillae or nests of cuboidal to columnar epithelial cells. The six cases of encapsulated papillary carcinoma showed nuclei of low to mild grade. All intraductal papilloma with usual ductal hyperplasia showed myoepithelial cells, interposed between the fibrovascular cores and the epithelial cell layer.
The six cases of solid papillary carcinoma consisted of multiples solid nodules, with rare thin fibrovascular cores that were difficult to highlight. In these tumors, epithelial cells may sometimes harbor neuroendocrine features with eosinophilic granulations in cytoplasms. Areas of spindle cells were observed in one case. Rare pool of extracellular mucin was also described in few cases of SPC.
For invasive micropapillary carcinoma, tumors showed more irregular margins. Tumor cells were arranged in micropapillae separated from the stroma by an empty clear space and forming clusters of carcinomatous cells, without stromal cores. Nuclear polarity abnormalities sometimes mimicking inverted polarity were described in the six cases.
Immunohistochemical features
Tumor cells of solid papillary carcinoma with reverse polarity showed a diffuse and strong cytoplasmic expression with CK7 (9/9 cases diffuse). Eight of nine cases showed positive staining with CK5/6 except for one case (case 9). Myoepithelial markers, p63 and calponin, were negative in 100% of solid papillary carcinoma with reverse polarity (0/9), 100% of encapsulated papillary carcinoma (0/6), of invasive micropapillary carcinoma (0/6) and of solid papillary carcinoma (0/ 6). Contrariwise, immunostaining with both markers was observed in intraductal papillomas with usual ductal hyperplasia (6/6), along the fibrovascular cores or in the capsule surrounding the lesion. Breast origin supported by GCDFP-15 staining was seen in 78% of solid papillary carcinomas with reverse polarity (7/9 cases focal) and in 78% of other group tumors (14/24). Rare scattered reactivity for hormonal receptors (ER, PR) not exceeding more than 5% of nuclei was identified in seven of nine cases of solid papillary carcinomas with reverse polarity (78%). Expression of HER2 was negative for all solid papillary carcinomas with reverse polarity. Expression of AR was absent or low (≤10%) in 78% of these tumors. The 24 other papillary breast tumors studied showed a higher hormonal receptor expression (ER, PR and AR) ranging from 50 to 100% of positive tumor cells. Expression of HER2 in these other papillary breast tumors was negative (19/24) or weak (1+) (5/24). TTF1 was negative for all breast tumors studied. Seven solid papillary carcinomas with reverse polarity (78%) had a low Ki67 proliferation index valued at 1 or 2%. Two solid papillary carcinomas with reverse polarity showed higher Ki67 rate, case 4 and case 9 with 6 and 15% tumor cell positivity, respectively. Invasive micropapillary carcinoma showed the highest Ki67 proliferation rate, then solid papillary carcinoma, encapsulated papillary carcinoma and intraductal papilloma with usual ductal hyperplasia, with respectively mean Ki67 values estimated at 28%, 9%, 7% and 2%. All solid papillary carcinomas with reverse polarity showed calretinin expression (9/9: six cases strong and diffuse and three cases focal). Ninety two percent (22/24) of remaining cases were negative for calretinin. Two of six intraductal papillomas with usual ductal hyperplasia (33%) showed focal and weak calretinin staining. Chromogranin A and synaptophysin were negative in all the groups except in solid papillary carcinomas. In this group, weak and focal positive immunostaining with neuroendocrine markers was observed in 67 % of cases.
Main solid papillary carcinomas with reverse polarity immunohistochemical features are illustrated in Fig. 6a-f and all immunohistochemical results are detailed in Table 3 .
IDH2 expression
We observed a strong and diffuse positive staining of tumor cells in six solid papillary carcinomas with reverse polarity (6/9) with the IDH1/2 mutant antibody ( Fig. 7) with a Hscore ranging from 120 to 300 (mean H-score: 191). One tumor (case 8) showed a weak immunolabeling with this antibody (H-score: 50). All breast tumors in other groups were negative with this IDH1/2 mutant antibody, except NA not assesable, PR progesterone receptor, TTF1 thyroid transcription factor 1 a Cases: 1 to 9=solid papillary carcinoma with reverse polarity; 10 to 15=invasive micropapillary carcinoma; 16 to 21=encapsulated papillary carcinoma; 22 to 27=intraductal papilloma with usual ductal hyperplasia; 28 to 33=solid papillary carcinoma two cases of intraductal papilloma with usual ductal hyperplasia that were weakly and focally stained (low H-score ≤40). Normal breast epithelial cells surrounding proliferation were not stained by this antibody. Main differences including both pathologic and immunohistochemical features between these five groups are summarized in Table 4 .
Molecular analysis
Genetic and transcriptomic profiles of solid papillary carcinomas with reverse polarity Exome analysis of the 9 solid papillary carcinomas with reverse polarity (cases 1 to 9) and the 24 control samples (invasive micopapillary carcinomas: cases 10 to 15; encapsulated papillary carcinomas: cases 16 to 21; intraductal papillomas with usual ductal hyperplasia: cases 22 to 27; and solid papillary carcinomas: cases 28 to 33) revealed that IDH2 harbored a hotspot mutation located on the arginine 172 (changed in glycine, serine or threonine) that was observed in 78% (7/9) of solid papillary carcinomas with reverse polarity and not in any controls. All gene variations are summarized in Table 5 .
Other genes were more often altered in solid papillary carcinomas with reverse polarity than in the control groups. Among these genes, we also found PRUNE2 that showed variations in 67% (6/9) in this group and in 17% (4/24) of the controls, with a recurrent splicing mutation observed in three solid papillary carcinomas with reverse polarity. The ACACB gene harbored variations in 56% (5/9) and in 8% (2/24) of controls. All solid papillary carcinomas with reverse polarity showed an alteration in, at least, one of CK5/6 and CK7 cytokeratins 5/6 and 7, EPC encapsulated papillary carcinoma, ER estrogen receptor, IDH2 isocitrate dehydrogenase 2, IDPUDH intraductal papilloma with usual ductal hyperplasia, IMPC invasive micropapillary carcinoma, SPC solid papillary carcinoma, SPCRP solid papillary carcinoma with reverse polarity these genes. We also analyzed variations in TET2 and PIK3CA genes. In all samples, we identified five mutations in TET2 with only one in an IDH2 wild-type solid papillary carcinoma with reverse polarity. Concerning PIK3CA, 67% (6/9) of these tumors had an activating mutation and 41% (10/24) of controls. Concomitant mutation in PIK3CA and IDH2 genes were identified in 56% of solid papillary carcinomas with reverse polarity (5/9 cases). Transcriptomic analysis revealed that solid papillary carcinomas with reverse polarity presented a specific RNA expression profile of 76 overexpressed genes compared to controls (Fig. 8) . The pathway enrichment analysis, performed with these 76 genes by the Enrichr website, highlighted that, in the KEGG (Kyoto Encyclopedia of Genes and Genomes) database, only one pathway was significantly (adjusted p = 0.0011) enriched in solid papillary carcinomas with reverse polarity group: proteoglycans. Intrinsic subtype classification made from RNA-sequencing showed that five of the nine tumors were considered as luminal A and four other as basal. This classification associated to the immunophenotype profile (CK5/6, ER and Ki 67) is summarized in Table 6 .
Discussion
Solid papillary carcinomas with reverse polarity represent a specific group of rare breast neoplasms consisting of papillary architecture, which may resemble morphologically to other benign or malignant breast lesions. In this study, we characterize, in comparison with intraductal papillomas with usual ductal hyperplasia, encapsulated papillary carcinomas, solid papillary carcinomas and invasive micropapillary carcinomas, and the morphologic, immunohistochemical and genomic profiles of this rare papillary tumor. From these three perspectives, we show that this papillary breast tumor was different from the other papillary breast lesions studied. In terms of genetic alterations, thanks to whole-exome analysis by next-generation sequencing, we confirm one noticeable genetic alteration in this group, totally absent in others tumor controls, which is an IDH2 hotspot mutation at R172 (7/9 cases). We identified other gene variations like PRUNE2 and ACACB that were also significantly present in this category compared to the other tumor controls. From the transcriptomic analysis, a specific RNA expression profile of 76 overexpressed genes was identified compared to controls.
On microscopic examination, solid papillary carcinoma with reverse polarity has effectively a papillary, solid or cystic architecture, as can be observed in papilloma and in encapsulated papillary carcinoma. In this tumor, papillary cores are lined by cuboidal to columnar epithelial cells. Nuclei often own grooves, clearing aspects and some pseudoinclusions. Sometimes, scattered eosinophilic secretions are seen within the proliferation. Historically, this is precisely those histological and cytological features that resemble the tall cell variant of papillary thyroid carcinoma, suggesting a possibility of metastasis from the thyroid. Eusebi et al. [3] first drew attention on these histologic features close to papillary thyroid carcinoma. This resemblance has been addressed with in previous studies [5, 6] . Thyroid markers such as TTF1 and thyroglobulin, enabling to characterize nearly 100% of papillary thyroid carcinomas [17] , were tested on all solid papillary carcinomas with reverse polarity and were always negative in previous studies [3, [5] [6] [7] [8] [9] [10] [11] [12] . In the present study, mutations associated to papillary thyroid carcinoma as BRAF or RET were not identified in our series of solid papillary carcinoma with reverse polarity, as in the Hameed et al. [4] study, with a special focus on BRAF V600E that had been recently Prediction of pathogenicity obtained with the PROVEAN website described as frequently associated to the tall variant of papillary thyroid carcinoma [18] . Extensive molecular analysis of this thyroid carcinoma did not reveal altered genes in common with solid papillary carcinoma with reverse polarity of the breast except PIK3CA [19] . Despite this resemblance, the hypothesis of any link between thyroid carcinoma and this papillary breast tumor has definitely been abandoned.
One of the striking morphologic features that can be helpful to recognize this peculiar papillary breast tumor is the nuclear reverse polarity of the epithelial cells. This finding is recurrent in the cases studied and is not present in the comparative groups. To note, on microscopy, invasive micropapillary carcinomas display abnormalities of polarity but not strict reverse nuclear polarity that is defined by the presence of nuclei near the apical layer. In a series of 13 solid papillary carcinomas with reverse polarity, Chiang et al. [10] also noticed that nuclei were present at the apical side rather to basal pole of the cells. In the present study, transcriptomic analyses revealed a proteoglycan pathway enrichment (KEGG database). Proteoglycans are implicated in cellular growth and differentiation control [20] . Glypican belongs to proteoglycans family and has been described in breast cancer with different conclusions [21, 22] but the understanding of functions is still limited. The control of cell polarity in zebrafish by one of the glypican family members has been established in a functional study [23] . The significant enrichment of this pathway in solid papillary carcinoma with reverse polarity could partially explain the polarity alteration of these tumors but needs to be explored in more detail.
From an immunohistochemical perspective, solid papillary carcinomas with reverse polarity are defined by the lack of any myoepithelial cell and, therefore, by the absence of immunostaining with myoepithelial markers (p63 and calponin). This point is crucial to diagnose this tumor and may support the hypothesis, although controversial that solid papillary carcinoma with reverse polarity is not strictly speaking an in situ carcinoma, at least like encapsulated papillary carcinoma and solid papillary carcinoma [24] . They also present a low Ki67 proliferation index and a low hormonal receptor rate. Another interesting point in this study was the unexpected immunostaining with calretinin. In this study, most of solid papillary carcinomas with reverse polarity were stained by this antibody (7/9 cases). We also observed that two papillomas were focally positive with calretinin. Calretinin is a calcium-binding protein, widely used to identify mesothelial origin, especially mesothelioma or some ovarian sex cord tumors. Calretinin expression has already been reported in normal breast tissues and breast carcinoma [25] . In three studies, this marker was associated to breast carcinoma of worse prognosis, especially of basal-like phenotype [26] [27] [28] .
To the best of our knowledge, this is the first study that compares solid papillary carcinoma with reverse polarity and other breast papillary and micropapillary lesions on three overriding and complementary perspectives. The rarity of cases reported in literature, the absence of this entity in the 2012 WHO (World Health Organization) classification of breast tumors [29] suggests that this papillary breast tumor was actually not well known. The point is that it effectively shares common characteristics with other papillary lesions, besides the papillary pattern. To begin, solid papillary carcinomas with reverse polarity share grooved nuclei and pseudo inclusions with intraductal papillomas with usual ductal hyperplasia. These cytological aspects had already been described arising in papilloma with usual ductal hyperplasia [30] . Both also express CK5/6 and have a low Ki67 proliferation index. The main difference between these lesions is the presence of myoepithelial cells in papilloma. Encapsulated or solid papillary carcinoma and invasive micropapillary carcinoma have in common with solid papillary carcinoma with reverse polarity the lack of myoepithelial cells, emphasized by the absence of calponin and p63 immunostaining. The main difference between these three lesions and solid papillary carcinoma with reverse polarity is the CK5/6 negativity and the strong hormonal receptor positivity in these three groups.
Thanks to the whole comparative analysis of these five close groups of breast tumor, we highlighted in terms of molecular data some specific features supporting the singularity of solid papillary carcinoma with reverse polarity.
Indeed, one of the most interesting findings highlighted by the molecular analysis is certainly that they harbored a recurrent IDH2 hotspot mutation at R172 (7/9 cases), whereas no other papillary breast lesion studied in this series harbored it. Thereby, this particular IDH2 mutation appears as a distinctive criterion and could characterize it. This result perfectly agrees with those of Chiang et al. [10] .
They recently described IDH2 mutations in 10 of 13 tumors and defined it with concomitant PIK3 alteration as a molecular signature through their functional study. Recently, Bhargava et al. [9] also highlighted this mutation in two of three tumors. IDH2 mutation is not frequent in breast pathology and has been described in several malignant tumors such as gliomas [31] , myeloid malignancies [32] , and also intrahepatic cholangiocarcinomas [33] , cartilaginous and bone tumors [34] [35] [36] . Usually, IDH gene encodes for one enzyme that catalyzes the conversion of Isocitrate into alpha ketoglutarate (alphaKG) [37] . When the mutation occurs at arginine 172 in gene encoding for IDH2, a function gain is seen. The enzyme is then able to produce an oncometabolite 2-hydroxyglutarate (2-HG). Comprehensive studies demonstrated that the production of this oncometabolite leads to a block in cellular differentiation in tumor [38] or increase of stem cells in leukemia [39] .
Faced with this particular mutation found in our series, and previously described in two recent studies [9, 10] , we sought to find a simpler way to identify IDH2 mutations by IHC. Indeed, we are the first to describe in breast, positivity for an IDH1/2 mutant antibody (MsMab-1), in correlation with the genomic mutation. Indeed, we tested this multispecific antibody of the IDH1/2 mutant protein (at arginine 172) on all cases of the study. Six of the seven solid papillary carcinomas with reverse polarity harboring an IDH2 mutation were stained by MsMab-1 with a H-score of >100. These results demonstrated a strong correlation between immunochemistry and exome data and can be useful to determine IDH2 mutations before DNA sequencing. To note, the MsMab-1 efficiency has been reported in two others studies, demonstrating positivity in giant cell tumor of bone [34, 40] and in osteosarcoma [36] .
We identified PRUNE2 gene mutations in 67% of solid papillary carcinoma with reverse polarity including the two tumors IDH2 wild type. PRUNE2 gene has been explored in prostate cancer [41] and parathyroid carcinoma [42] , and could suppress the cellular transformation [43] .
The phosphatidylinositol-3-kinase (PIK3) cell signaling pathway is often dysregulated and activated in human cancers, and in more than half of breast invasive tumors [44] . We identified PIK3CA or PIK3R1 alterations in all our study groups, regardless of malignancy. Indeed, this alteration does not appear specific, and we identified it in 67% of solid papillary carcinomas with reverse polarity. Concerning PIK3CA, 67% of solid papillary carcinomas with reverse polarity had an activating mutation and 41% other papillary breast tumors. Troxell et al. [45] identified PIK3CA alteration in papillary neoplasms of the breast with a high prevalence, especially for papilloma with usual ductal hyperplasia. In our series, we also identified a TET2 mutation occurring in one IDH2 wild-type solid papillary carcinoma with reverse polarity similar to the one described in the Chiang et al. [10] study. However, TET2 mutation was also present in four other papillary breast lesions in our series.
In this particular tumor and in this small number of cases, we did not find any concordance between intrinsic molecular classification and immunophenotypic profile (CK5/6, ER, Ki67). In other breast tumors, correlation between immunochemistry profile and molecular classification is not always absolute. In Nielsen et al. [46] series, 10% of breast tumors were assigned to nonluminal subtypes despite their ER positivity. In the same way, Rakha et al. [47] demonstrated that some cases of triple-negative tumors are not always basal-like tumors.
Concerning the prognosis of solid papillary carcinoma with reverse polarity, despite the low number of available follow-up of patients in the present series for this group and in literature, only four patients presented lymph node metastasis [5, 6, 12] with one associated to bone metastasis [6] . The low prevalence of reported metastasis in literature, subject to not only the current number of reported cases, but also the low Ki67 proliferation index, the well-delimited morphology and the absence of necrosis or mitoses, strongly suggest these tumors are of favorable prognosis. Further studies are warranted to better assess their prognosis. However, in the event of an unlikely metastatic evolution, the presence of an IDH2 mutation could enable the use of IDH2 inhibitors currently under development for hematologic malignancies [48] .
In summary, despite the small number of solid papillary carcinoma with reverse polarity in this series, it represents the third largest described in the literature. We highlight microscopic-, immunohistochemical-and molecularspecific features that distinguish this breast tumor from other breast papillary and micropapillary lesions. Reverse nuclear polarity, nuclear grooves, lack of myoepithelial cells, low or negative hormonal receptor expression, positivity for CK5/6, calretinin and IDH2 mutant antibody together represent the hallmark of this tumor. In addition, solid papillary carcinoma with reverse polarity harbors frequent specific mutations as IDH2 (R172) and/or PRUNE2 that can help in the diagnosis of this rare and intriguing entity.
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